Crinetics Pharmaceuticals Inc Review Of Phase 2 Paltusotine Results Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : You talked about how 87% of the trial completers had at end of treatment IGF-1 levels within 20% of baseline or lower however, because the population enrolled, the baseline in EDGE was above the upper limit of normal. But you sort of alluded to this data informing a future trial that would involve a responder analysis. So I'm hoping you could just elaborate on what the take-home is from this result as it relates to future responder analyses in a pivotal population where presumably baseline would be under the upper limit of normal?

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Okay. Great. And then when I look at Slide 20 on the dose response data, the inter-quartile ranges seem to show a little more, call it, variability or skewed to the upside of IGF-1 than to the downside. Do you think there are any differences in exposure that might be at play there? And do you think this sort of pattern is what we should expect going forward?

Question: Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst : Okay. Great. And maybe just a last one on dose, kind of following up on some of the comments throughout the call just to make sure I understand. Do you think you found the doses to take forward? I think earlier on, you said maybe thinking about the higher end of the dose range here, say, 30 or 40 milligrams? Or do you anticipate exploring doses even higher than 40 milligrams in Phase III?